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Abstract
Background: Matrix metalloproteinases play an important role in extracellular matrix deposition
and degradation. Based on previous clinical observations of corneal perforations during topical
fluoroquinolone treatment, we decided to evaluate the comparative effects of various
fluoroquinolone eye drops on the expression of matrix metalloproteinases (MMPs) in cornea.
Methods:  Eighty female Lewis rats were divided into two experimental groups: intact and
wounded corneal epithelium. Uniform corneal epithelial defects were created in the right eye with
application of 75% alcohol in the center of the tissue for 6 seconds. The treatment groups were
tested as follows: 1) Tear drops: carboxymethylcellulose sodium 0.5 % (Refresh, Allergan); 2)
Ciprofloxacin 0.3% (Ciloxan, Alcon); 3) Ofloxacin 0.3%(Ocuflox, Allergan); 4) Levofloxacin
0.5%(Quixin, Santen). Eye drops were administered 6 times a day for 48 hours. Rats were sacrificed
at 48 hours. Immunohistochemical analysis and zymography were conducted using antibodies
specific to MMPs-1, 2, 8 and 9.
Results: MMP-1, MMP-2, MMP-8 and MMP-9 expression were detected at 48 hrs in undebrided
corneal epithelium groups treated with the topical fluoroquinolones. No statistical difference was
observed in quantitative expression of MMPs among ciprofloxacin 0.3%, ofloxacin 0.3%,
levofloxacin 0.5%. When the artificial tear group and the fluoroquinolone groups with corneal
epithelial defect were compared, increased expression of MMPs was observed as a result of the
wound healing process. However, the fluoroquinolone treated group exhibited high statistically
significantly levels of MMPs expression.
Conclusions: Our study provides preliminary evidence that topical application of fluoroquinolone
drugs can induce the expression of MMP-1, MMP-2, MMP-8 and MMP-9 in the undebrided corneal
epithelium compared to artificial tear eye drops.
Background
Since their introduction in the United States over a decade
ago, the quinolone antibacterial agents have become a
mainstay in the treatment of serious bacterial infections.
Published: 06 October 2003
BMC Ophthalmology 2003, 3:10
Received: 23 April 2003
Accepted: 06 October 2003
This article is available from: http://www.biomedcentral.com/1471-2415/3/10
© 2003 Reviglio et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/10
Page 2 of 8
(page number not for citation purposes)
The fluoroquinolones are known for their extremely
broad spectrum of antibacterial activity.[1,2] They exert a
bactericidal effect by inhibiting bacterial DNA synthesis
through interference with the enzymes DNA gyrase and
topoisomerase IV. The structural differences of the fluori-
nated carboxyquinolones commercially available, for top-
ical ophthalmic use, alter their potency as well as their
pharmacological profiles. To be clinically useful, antibiot-
ics should be effective with minimal adverse effects.
Although fluoroquinolones have been shown to be highly
effective antibacterial agents, several clinical studies have
reported a fluoroquinolone-induced tendinopathy with
bone and articular damage associated with alterations in
collagen deposition and chondrocyte function after sys-
tematic fluoroquinolone administration. [3–5] Topical
fluoroquinolone antibiotics are frequently administered
prophylactically in post-surgical care and represent a ther-
apeutic option in the treatment of infectious conjunctivi-
tis and keratitis.[2] These are generally well tolerated and
compare favorably with other topical antibiotics in terms
of efficacy. However, it is interesting to note that most of
the commercial fluoroquinolone ophthalmic solutions
contain very low concentrations of the preservatives ben-
zalkonium chloride or edetate disodium (Ciloxan at
0.006%, Ocuflox at 0.05 mg and Quixin at 0.005%) in
their formulations. As it is known, much of the reported
toxicity has been associated with the presence of certain
preservatives in high concentrations (close to 0.1%)
which is not the case with the current fluoroquinolone
formulations studied. [6]In vivo animal and in vitro studies
have also demonstrated that fluoroquinolone agents may
adversely affect wound healing by exerting cytotoxic
effects on corneal epithelial cells and keratocytes; how-
ever, the exact mechanism of fluoroquinolone toxicity is
still unknown. [7–10]
A recent study reported an increased incidence of ulcera-
tive keratolysis with corneal perforation after topical fluo-
roquinolone treatment for microbial keratitis.[11] These
findings led us to investigate the role of various commer-
cially available fluoroquinolone eye drop formulations
on the physiological remodeling of the corneal extracellu-
lar matrix by evaluating matrix metalloproteinase expres-
sion in cornea.
Matrix metalloproteinases (MMPs) are involved in
numerous physiological and pathological processes of
corneal extracellular matrix remodeling and degradation.
[12–14] The proteolytic properties of these enzymes may
play an important role in the unidentified mechanism of
ulcerative keratolysis associated with the topical use of
fluoroquinolone eye drops. The MMPs can be grouped
into different subclasses according to their natural sub-
strates. We focused on two specific groups: collagenases
and gelatinases; evaluating the expression of interstitial
collagenase (MMP-1) and PMN collagenase (MMP-8),
both of which can be secreted by corneal cells and are able
to cleave corneal stromal collagens. We assessed the
expression of 72-kDa gelatinase A (MMP-2) and 92-kDa
gelatinase B (MMP-9) as well. These gelatinases help to
degrade the basement membrane and act cooperatively
with the collagenases to completely degrade interstitial
corneal collagens.
Methods
Eighty female Lewis rats each weighing 250 g were first
divided into two experimental groups. Each rat was pre-
pared to produce a debrided corneal epithelium in the
right eye and intact corneal epithelium in the left eye. The
animals were then randomly divided into four experimen-
tal test groups of 20 rats each, as follows: Group 1 received
tear drops consisting of carboxymethylcellulose sodium
0.5% (Refresh, Allergan, Irvine, CA); Group 2 received
ciprofloxacin 0.3% (Ciloxan, Alcon, Fort Worth, TX);
Group 3 was instilled ofloxacin 0.3% (Ocuflox, Allergan,
Irvine, CA); finally, group 4 received levofloxacin
0.5%(Quixin, Santen, Napa, CA).
All of the animals were treated in accordance with the ten-
ets of the Association for Research in Vision and Ophthal-
mology (ARVO) statement for the use of animals in
Ophthalmic and Vision Research.
Anesthesia was achieved by intramuscular injection of 0.5
ml/kg body weight of a mixture 1:1 of 100 mg/ml keta-
mine and 20 mg/ml xylazine. Uniform corneal epithelial
defects were created in the right eyes with the application
of a filter paper disk soaked in 75% ethanol solution in
the center of the tissue for 60 seconds. Immediately after
the procedure, treated eyes were thoroughly irrigated with
balanced salt solution. The left eye served as an intact epi-
thelium control in each rat. Eye drops were instilled six
times/day for 48 hours. Rats were sacrificed at 48 hours
after initiation of treatment. The corneas from fifty six rats
were removed at the scleral ring, embedded in ornithine
carbamoyltransferase compound (OCT Tissue-Tek, Miles
Inc., Elkhart, USA), and frozen at -80°C. Cryostat sections
of 8 µm from all corneas were stained with hematoxylin
and eosin, or immunohistochemically using antibodies
specific for MMP-1, MMP-2, MMP-8 and MMP-9. We used
six rats from each treatment group (n = 24) to perform
immunoblotting and zymography studies.
Immunohistochemistry
Immunohistochemical staining was performed using an
avidin-biotin-peroxidase complex technique. Primary
antibodies consisted of polyclonal antibodies recognizing
epitopes of both the pro- and active forms of MMP-1 and
MMP-8 (Chemicon, Temecula, CA) as well as monoclonal
antibodies against MMP-2 and MMP-9 (Oncogene,BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/10
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Cambridge, MA and Chemicon, Temecula, CA respec-
tively). The primary antibodies were applied to the cor-
neal sections and incubated at room temperature for 1
hour. After washing with TBS (20 mM Tris-HCl pH 7.5,
150 mM NaCL), a biotin-labeled secondary antibody,
either goat anti-rabbit or horse anti-mouse IgG (Vector
Laboratories, Burlingame, CA) was used. Finally, after
incubation with the avidin-biotin-peroxidase complex
(Vector Laboratories, Burlingame, CA), slides were devel-
oped in 3,3' diaminobenzidine and counterstained with 1
% methyl green in methanol. Analysis of immunostaining
was performed to determine possible statistical signifi-
cance between the artificial tear group and the fluoroqui-
nolone treated groups. All samples were stained in
parallel to minimize specimen variation and cell staining
intensity was graded by a masked observer. A statistical
calculation and significant differences in immunostaining
between the treated groups and the artificial tear control
group were defined as p < 0.05 by Fisher's exact test.
To quantify the metalloproteinase expression after the
application of fluoroquinolone eye drops, the four test
groups were analyzed by western-blot and zymography.
Zymography
MMP-2 and MMP-9 levels were also assayed by zymogra-
phy. Debrided (n = 24) and intact rat corneas (n = 24)
from the four treatment groups were dissected and tre-
phined (3 mm) at 48 hours and immediately cultivated in
a 24-well culture dish with 500 µl of serum-free medium
(MEM + minimal essential amino acid + antibiotic/
antimycotic) at 37°C, 5% CO2 atmosphere for 72 hours.
Each and every conditioned media aliquot was subjected
to gel electrophoresis (10% SDS polyacrylamide gel con-
taining 1 mg/ml gelatin) under nonreducing conditions.
Fifteen microliters of each conditioned medium and
zymography sample buffer were combined and incubated
at room temperature for 5 minutes. Electrophoresis was
carried out at 100 to 150 volts for 2–4 hours. The gels were
washed in renaturing buffer (Bio-Rad Laboratories, Her-
cules, CA) for 30 minutes at room temperature, incubated
with development buffer (Bio-Rad) at 37°C for 16 hours,
stained for 3 hours with Coomassie Brillant Blue R-250,
and destained with three changes (15, 30, 60 minutes) of
destain solution (Bio-Rad Laboratories).
Immunoblot Assays
The levels of MMP-1 and MMP-8 in the cornea-condi-
tioned culture medium were assessed by Western blot.
The blot was probed with polyclonal antibodies against
MMP-1 or MMP-8, (Chemicon, CA). Fifteen microliters of
conditioned medium was mixed with electrophoresis Lae-
mmli buffer and heated at 90°C for 5 minutes, and then
kept on ice. The samples were run on 10% polyacrylamide
SDS gel at 100 volts for 2 hours, and transferred to nitro-
cellulose membranes at 120 volts for 2 hours (Bio-Rad
Richmond, CA). The nitrocellulose paper was agitated in
blocking buffer at room temperature (PBS, 0.05% Tween
20, 0.5% non-fat dry milk) for 1 hour. The primary anti-
body (1:5000 dilution) and secondary antibody (1:2000
dilution) incubations were carried out for 1 hour respec-
tively. After three washes with TBS-T (TBS, 0.05% Tween-
20), the membranes were incubated in enhanced chemi-
luminescence solution (Amersham Life Science, Arlington
Heights, IL) followed by exposure to chemiluminescence
film for 15 seconds.
Statistical Analysis
The western blots and zymograms from all treated eyes,
each one in duplicate were subjected to densitometry
analysis. The statistical analysis was done using one-way
ANOVA test, Dunnett's multiple comparison test and
Bonferroni test (SPSS, ver. 10.0 for Windows; SPSS Inc.,
Chicago, IL) and Microstat-Ecosoft Inc. (Indianapolis,
Inc.), the values lower than 0.05 was considered statisti-
cally significant (fluoroquinolone treated groups com-
pared to artificial tear treated group as control). The
quantification of metalloproteinase values of each X-ray
film and gel zymograms from all treated eyes were per-
formed by scanning densitometry (Molecular Dynamics,
Sunnyvale, CA).
Results
Using immunohistochemical staining we found positive
collagenases MMP-1 and MMP-8 staining in the wounded
corneal epithelium of the artificial tear group and the
absence of MMP staining in the unwounded eyes of the
same group (Table 1). These results are consistent with an
established correlation between the wound healing and
extracellular matrix remodeling process and the up-regu-
lation of MMPs. The current artificial tear solution was
demonstrated to be innocuous to the corneal tissue and
did not have any effect on the expression of corneal met-
alloproteinases in unwounded corneal epithelium.
We also examined the MMP expression after the applica-
tion of commercially available fluoroquinolone eye
drops. Analysis of immunohistochemical staining dis-
closed a positive staining for metalloproteinase at corneal
epithelium and superficial stroma. Interestingly, the per-
centage of eyes positively staining for MMP-1 and MMP-8
was not found to be significantly different between
unwounded groups treated with each of the commercially
available fluoroquinolone eye drops. This result indicates
that the fluoroquinolone ophthalmic solutions are the
major trigger for the increased expression of these MMPs
in the normal corneal epithelium. In previous studies, we
also observed MMP-8 expression at the level of the corneal
epithelium associated with ulcerative keratolysis. These
findings identify a novel source of MMP-8 expression atBMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/10
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Table 1: Effects of Topical fluoroquinolones on Collagenase-type Metalloproteinases Immunohistochemical detection at 48 Hours
Type of eye drops MMP-1 MMP-8
Applied q.i.d. Epithelium
Artificial Tear Intact 0/14 0/14
Debrided 14/14 13/14
Ciloxan Intact 14/14 ** 13/14 **
Debrided 14/14 14/14
Ocuflox Intact 13/14** 12/14**
Debrided 14/14 14/14
Quixin Intact 13/14** 12/14**
Debrided 14/14 14/14
Double masked observer determined the total positive immunostained eyes for MMP-1 and MMP-8 in each test group. Immunoreactivity is 
reported as number of positively immunostained corneas / total number of corneas examined. ** Statistically different when comparing the 
corresponding fluoroquinolone group to artificial tear. (P < 0.05 using Fisher's exact test analysis).
Immunolocalization of MMP-1 in intact corneal epithelium at 48 hours is shown for each treatment group Figure 1
Immunolocalization of MMP-1 in intact corneal epithelium at 48 hours is shown for each treatment group. Panel a: artificial 
tears; panel b: Ciprofloxacin 0.3%; panel c: Ofloxacin 0.3%; panel d: Levofloxacin 0.5%. A photomicrograph of the artificial tear 
group shows negative corneal staining for MMP-1. However, intense corneal epithelial and superficial stromal expression of 
MMP-1 was identified in intact corneal epithelium groups treated with fluoroquinolone eye drops (panel's b-d). The presence 
of MMP-1 was detected mostly in the corneal epithelial cells (arrows). (Immunohistochemistry, ×400 magnification).BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/10
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the corneal epithelial cells as a non-PMN cellular source
of this collagenase. Using hematoxylin-eosin stain, the
polymorpho nuclear neutrophils (PMNs) were identified
on the basis of their characteristic multilobed nucleus and
staining pattern. In the current study, the fluoroquinolone
treatment causes a non significant increase of PMNs in
unwounded corneas compared to the artificial tear group
at 48 hours. Figure 1 illustrates MMP-1 immunostaining
primarily in the epithelial cells and occasionally in the
superficial stromal keratocytes of intact corneas of the
fluoroquinolone treated groups.
To confirm the results illustrated by immunohistochemi-
cal staining and to provide a more accurate quantitative
analysis, we used western blotting and zymography tech-
niques to study the early MMP expression after fluoroqui-
nolone eye drop treatment. The values of each MMP
bands from western blots and zymography studies made
in all treated eyes were quantified by densitometry analy-
sis and also studied statistically to indicate any signifi-
cance between each fluoroquinolone treated groups and
the artificial tear group (Figure 4A through 4D).
A comparison of topical artificial tear group as control ver-
sus groups treated with ciprofloxacin, ofloxacin and levo-
floxacin on the expression of corneal metalloproteinases
was conducted. These studies also disclosed that the appli-
cation of the present ophthalmic fluoroquinolone solu-
tions (Ciloxan, Ocuflox and Quixin) increases MMP-1,
MMP-8 (immunoblots, figure 2) and MMP-2, MMP-9
(zymography, figure 3) expression in both intact and
wounded corneas although the levels of expression may
be slightly different among various groups. In accordance
with our previous findings, treatment with the artificial
tear does not appreciably induce the expression of MMPs
in intact corneal epithelium. The MMP up-regulation
detected in all groups of wounded eyes presumably
resulted from the wound healing process and extracellular
matrix remodeling. However, the expression of MMPs in
wounded eyes was up-regulated by the topical application
of the fluoroquinolone drugs when compared to the arti-
ficial tear treated group. The results presented in this study
demonstrated a statistically significant difference between
fluoroquinolone treated groups (P < 0.0001) versus artifi-
cial tear treated group as control in the expression of cor-
neal metalloproteinases.
Conclusions
Fluoroquinolones are one class of synthetic antibacterial
agents, which inhibit the bacterial topoisomerases
involved in bacterial DNA replication. Since the 1980s,
the U.S. Food and Drug Administration has approved sev-
A representative western blot of MMP-1 and MMP-8 expression of supernatant samples from control (artificial tear) and the  fluoroquinolone test groups Figure 2
A representative western blot of MMP-1 and MMP-8 expression of supernatant samples from control (artificial tear) and the 
fluoroquinolone test groups. Corneas with debrided (OD) and intact (OS) epithelium were analyzed. 1. MW; 2. Tears OS; 3. 
Tears OD; 4. Ciprofloxacin OS; 5. Ciprofloxacin OD; 6. Ofloxacin OS; 7. Ofloxacin OD; 8. Levofloxacin OS; 9. Levofloxacin 
OD The molecular sizes of both MMPs were calculated based on a molecular weight standard and recorded in kilodaltons 
(kDa). The fluoroquinolone eye drops increased the expression of both metalloproteinases, MMP-1 (42 kDa) and of MMP-8 
(64 kDa) in intact corneas; whereas, the expression of these MMPs was negative in the controls treated with artificial tears.BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/10
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eral generations of fluoroquinolones. Recently, levo-
floxacin 0.5% solution, a third generation
fluoroquinolone, was introduced as a commercial eye
drop for clinical use in therapy of acute bacterial conjunc-
tivitis. The unique structure of this drug differs from other
fluoroquinolones conferring high solubility to potentially
allow formulation at higher concentrations. It also
extends the Gram-positive spectrum; and enhances the
activity against anaerobic microbes while maintaining
Gram-negative activity.[1] Fluoroquinolones are generally
well tolerated with minimal side effects when used appro-
priately.[15] However, several in vitro and in vivo studies
have demonstrated that both ciprofloxacin and ofloxacin
eye drops significantly delay corneal wound heal-
ing.[7,8,16] In addition, ciprofloxacin hydrochloride
0.3% solution has demonstrated a tendency for precipita-
tion with corneal crystal deposition, mainly in association
with the pH dependent solubility of the eye drop formu-
lation.[17,18] The above mentioned studies suggest that
the current commercially available topical fluoroqui-
nolone agents, and their accompanying preservatives,
have cytotoxic effects on corneal cells.
The metalloproteinases are potent enzymes that are capa-
ble of degrading a wide range of extracellular matrix com-
ponents. Numerous studies have documented the
important role of matrix metalloproteinases in the cor-
neal wound healing process.[19,20] The perturbation of
the normal regulation of degradative processes may result
in the accelerated breakdown of connective tissues and
may lead to conditions such as ulcerative keratolysis.
There is increasing experimental and clinical evidence that
during corneal injury and inflammation, MMPs play a
major role in the proteolytic processes, which can predis-
pose the cornea to perforation.[21] Thus, this study
focuses on evaluating the expression of MMPs after the
use of commercially available fluoroquinolone eye drops
in order to elucidate a relationship between keratolysis,
corneal perforation and the use of ophthalmic fluoroqui-
nolone drugs as reported in previous clinical studies.[11]
The findings in the current study provide the first evidence
that some undesirable effects on corneal wound healing
from the use of specific fluoroquinolone eye drops (or
their use in vulnerable corneal epithelium) may be sec-
ondary to the over-expression of the metalloproteinases.
Furthermore, the results of our study clearly demonstrate
that the commercial fluoroquinolone ophthalmic agents
tested stimulate expression of corneal collagenases (MMP-
1 and MMP-8) and gelatinases (MMP-2 and MMP-9) in
normal eyes compared to a negative expression of MMPs
in the artificial tear group. Additional studies are required
to confirm the exact cellular origin of MMP-8 expressed in
corneal tissue, although it is now recognized that cell
types other than PMNs can express this collagenase.
Recent in vivo and in vitro studies indicate that the patho-
logic mechanism with fluoroquinolones may be related to
significant increases of matrix-degrading proteolytic
Typical gelatin zymography analyses of gelatinase A (MMP-2) and gelatinase B (MMP-9) expression in artificial tear group rat  and in the test groups were performed Figure 3
Typical gelatin zymography analyses of gelatinase A (MMP-2) and gelatinase B (MMP-9) expression in artificial tear group rat 
and in the test groups were performed. Corneal conditioned medium samples from debrided (OD) and intact (OS) corneal 
epithelium of each group were analyzed. 1. Tears OD; 2. Tears OS; 3. Levofloxacin 0.5% OD; 4. Levofloxacin 0.5% OS; 5. Cip-
rofloxacin OD; 6. Ciprofloxacin OS; 7. Ofloxacin OD; 8. Ofloxacin OS. MMP-9 (92 kDa) and MMP-2 (72 kDa) expression were 
up regulated in fluoroquinolone treated corneas and were present at basal level in unwounded corneas receiving artificial tears. 
Corneal epithelium debridement up regulated the expression of MMP-9 and MMP-2 in all test groups.BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/10
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activity, inhibitory effects on cell metabolism, as well as
the degenerative and ultrastructural cell changes with
increased levels and interferences in the regulative path-
ways of several cytokines. [22–26] The clinical
significance of these findings revolve around two main
questions: how is the expression of these matrix metallo-
proteinase increased after the application of topical fluor-
oquinolone eye drops? and how significant are the eye
drop preservatives at low concentration in stimulating
MMP expression in the cornea? A new generation fluoro-
quinolone agent, moxifloxacin 0.5% (Vigamox, Alcon
Labs, Fort Worth, TX) is commercially formulated without
preservatives. Further studies addressing these important
questions and explaining the cascade of factors involved
in producing this increased expression of MMPs seem
warranted. Physicians should be aware of the possible
consequences of using fluoroquinolones for both normal
and impaired corneal tissue especially with a prophylactic
Effects of fluoroquinolone eye drops on the corneal rat's metalloproteinases expression Figure 4
Effects of fluoroquinolone eye drops on the corneal rat's metalloproteinases expression. The bands densities of western immu-
noblots for MMP-1 (A) and MMP-8 (B) and zymograms for MMP-2 (C), MMP-9 (D) were subjected to densitometry analysis, 
the statistical significance was determined by one-way ANOVA test (values are means, error bars). P < 0.05 was considered 
statistically significant when compared fluoroquinolones groups vs. artificial tear group. Note the highest values of MMPs levels 
from topical fluoroquinolone groups compared to artificial tear group in unwounded corneas.Publish with BioMed Central    and   every 
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aim. Clinical decisions should balance safety with efficacy
especially in the light of studies, such as this one, docu-
menting the potential for corneal cytotoxicity and wound
healing impairment after the topical application of com-
mercially available fluoroquinolone drugs.
Competing Interests
None declared.
Authors' Contributions
Victor E. Reviglio, MD: AB, JY
Melinda A. Hakim, MD: JY
Jae K. Song, MD: JY, ES
Terrence P. O'Brien, MD: FG
Victor E. Reviglio, Melinda A. Hakim and Jae K. Song car-
ried out animal model, sample preparation, microscopy,
immunostaining, zymography and immunoblotting.
Victor E. Reviglio and Terrence P. O'Brien were both
involved in the experimental design, data analysis and
preparation of manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thanks Dr. Juan C. Muiño for providing the sta-
tistical assistance.
References
1. Graves A, Henry M, O'Brien TP, Hwang DG, Van Buskirk A and
Trousdale MD: In Vitro Susceptibilities of Bacterial Ocular Iso-
lates to Fluoroquinolones. CORNEA 2001, 20:301-305.
2. O'Brien TP, Maguire MG, Fink NE, Alfonso E and McDonnell P: Effi-
cacy of ofloxacin vs cefazolin and tobramycin in the therapy
of bacterial keratitis. Arch Ophthalmol 1995, 113:1257-1265.
3. Harrell RM: Fluoroquinolone-induced tendinopathy. What do
we know? South Med J 1999, 92:622-625.
4. Huston KA: Achilles tendonitis and tendon rupture due to
fluoroquinolone antibiotics (Letter). N Eng J Med 1994, 331:748.
5. Redmond AO: Risk-benefit experience of ciprofloxacin use in
pediatric patients in the United Kingdom. Pediatr Infect Dis J
1997, 16(1):147-9. discussion 160–2
6. Burstein NL: Corneal cytotoxicity of topically applied drugs,
vehicles and preservatives. Surv Ophthalmol 1980, 25:15-30.
7. Cutarelli PE, Lass JH, Lazarus HM, Putman SC and Jacobs R: Topical
fluoroquinolones: antimicrobial activity and in vitro corneal
epithelial toxicity. Curr Eye Res 1991, 10:557-563.
8. Seitz B, Hayashi S, Wee WR, LaBree L and McDonnell PJ: In vitro
effects of aminoglycosides and fluoroquinolones on
keratocytes. Invest Ophthal Vis Sci 1996, 37:656-665.
9. Morlet N, Minassian D and Butcher J: Ofloxacin Study Groups.
Risk factors for treatment of suspected microbial keratitis. Br
J Ophthalmol 1999, 83:1027-1031.
10. Bekoe NA, Li Q, Ashraf F and O'Brien TP: Effects of ciprofloxacin,
ofloxacin and gentamicin on corneal cells and wound healing.
Invest Ophthalmol Vis Sci 1999, 40:S548.
11. Mallari PLT, McCarty DJ, Daniell M and Taylor H: Increased inci-
dence of corneal perforation after topical fluoroquinolone
treatment for microbial keratitis.  Am J Ophthalmol 2001,
131:131-133.
12. Massova I, Kotra LP and Fridman R et al.: Matrix metalloprotein-
ases: structures, evolution and diversification. FASEB J 1998,
12:1075-1095.
13. Fini ME, Parks WC, Rinehart WB and Girard MT et al.: Role of
matrix metalloproteinases in failure to re-epithelialize after
corneal injury. Am J Pathol 1996, 149(4):1287-302.
14. Ye HQ and Azar DT: Statement of gelatinases A and B, and
TIMPs 1 and 2 during wound healing. Invest Ophthalmol Vis Sci
1998, 39(6):913-21.
15. Leibowitz HM: Antibacterial effectiveness of ciprofloxacin 3%
ophthalmic solution in the treatment of bacterial
conjunctivitis. Am J Ophthalmol 1991, 112(4 Suppl):29S-33S.
16. Moreira LB, Lee RF, Oliveira C, LaBree L and McDonnell PJ: Effect
of topical fluoroquinolones on corneal re-epithelialization
after excimer laser keratectomy. J Cataract Refract Surg 1997,
23:845-848.
17. Essepian JP, Rajpal R and O'Brien TP: Tandem scanning confocal
microscopic analysis of ciprofloxacin corneal deposits in
vivo. Cornea 1995, 14:402-407.
18. Kanellopoulos AJ, Miller F and Wittpenn JR: Deposition of topical
ciprofloxacin to prevent re-epithelialization of corneal
defect (Letter). Am J Ophthalmol 1994, 117:258-259.
19. Fini ME, Yue YJT and Sugar J: Collagenolytic / gelatinolytic met-
alloproteinases in normal and keratoconus corneas. Curr Eye
Res 1992, 11:849-62.
20. Birkedal-Hansen H, Moore WG and Bodden MK et al.: Matrix met-
alloproteinases: a review.  C r i t  R e v  O r a l  B i o l  M e d  1993,
4(2):197-250.
21. O'Brien TP, Li QJ, Sauerburger F and Reviglio VE et al.: The role of
matrix metalloproteinases in ulcerative keratolysis associ-
ated with perioperative diclofenac use.  Ophthalmology 2001,
108:656-659.
22. Riesbeck K, Sigvardsson M, Leanderson T and Forsgren A: Superin-
duction of cytokine gene transcription by ciprofloxacin.  J
Immunol 153(1):343-52. 1994 Jul 1
23. Williams RJ III, Attia E, Wickiewicz TL and Hannafin JA: The effect
of ciprofloxacin on tendon, paratenon, and capsular fibrob-
last metabolism. Am J Sports Med 2000, 28(3):364-9.
24. Shakibaei M and Stahlmann R: Ultrastructure of Achilles tendon
from rats after treatment with fleroxacin. Arch Toxicol 2001,
75(2):97-102.
25. Egerbacher M, Seiberl G, Wolfesberger B and Walter I: Cipro-
floxacin causes Cytoskeletal changes and detachment of
human and rat chondrocytes in vitro. Arch Toxicol 2000, 73(10–
11):557-63.
26. Shakibaei M and Stahlmann R: Ultrastructural changes induced
by the des-F(6)-quinolone garenoxacin (BMS-284756) and
two fluoroquinolones in Achilles tendon from immature
rats. Arch Toxicol 2003.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2415/3/10/prepub